Compare KINS & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KINS | IMRX |
|---|---|---|
| Founded | 1886 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.4M | 265.3M |
| IPO Year | 2013 | 2021 |
| Metric | KINS | IMRX |
|---|---|---|
| Price | $19.91 | $4.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | 149.1K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 94.59 | 37.75 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $214,867,301.00 | N/A |
| Revenue This Year | $24.23 | N/A |
| Revenue Next Year | $18.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 38.50 | N/A |
| 52 Week Low | $13.08 | $2.90 |
| 52 Week High | $20.79 | $10.08 |
| Indicator | KINS | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.28 | 38.87 |
| Support Level | $14.37 | $3.95 |
| Resistance Level | $20.79 | $5.36 |
| Average True Range (ATR) | 0.70 | 0.27 |
| MACD | -0.22 | -0.09 |
| Stochastic Oscillator | 51.03 | 3.15 |
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.